Koers Xeris Biopharma Holdings, Inc. Nasdaq
Aandelen
XERS
US98422L1070
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 184 mln. 171 mln. | Omzet 2025 * | 219 mln. 204 mln. | Marktkapitalisatie | 310 mln. 288 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -55 mln. -51,04 mln. | Nettowinst (verlies) 2025 * | -27 mln. -25,06 mln. | EV/omzet 2024 * | 1,68 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,42 x |
K/w-verhouding 2024 * |
-5,74
x | K/w-verhouding 2025 * |
-12,1
x | Werknemers | 377 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,13% |
Recentste transcriptie over Xeris Biopharma Holdings, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 60 | 01-01-05 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05-10-21 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05-10-21 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05-10-21 |
Marla Persky
BRD | Director/Board Member | 68 | 05-10-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,30% | 46,03 mld. | |
+52,73% | 44,55 mld. | |
+7,15% | 40,8 mld. | |
-8,78% | 28,25 mld. | |
+18,68% | 27,71 mld. | |
-21,92% | 18,82 mld. | |
+14,62% | 13,91 mld. | |
+31,85% | 12,43 mld. | |
+4,47% | 10,81 mld. |